Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2016 | 1 |
2019 | 1 |
2020 | 2 |
2022 | 1 |
2023 | 1 |
2024 | 0 |
Search Results
6 results
Results by year
Filters applied: . Clear all
Page 1
Modulation of ERK5 Activity as a Therapeutic Anti-Cancer Strategy.
J Med Chem. 2023 Apr 13;66(7):4491-4502. doi: 10.1021/acs.jmedchem.3c00072. Epub 2023 Apr 1.
J Med Chem. 2023.
PMID: 37002872
Free PMC article.
Review.
Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor.
Miller DC, Reuillon T, Molyneux L, Blackburn T, Cook SJ, Edwards N, Endicott JA, Golding BT, Griffin RJ, Hardcastle I, Harnor SJ, Heptinstall A, Lochhead P, Martin MP, Martin NC, Myers S, Newell DR, Noble RA, Phillips N, Rigoreau L, Thomas H, Tucker JA, Wang LZ, Waring MJ, Wong AC, Wedge SR, Noble MEM, Cano C.
Miller DC, et al.
J Med Chem. 2022 May 12;65(9):6513-6540. doi: 10.1021/acs.jmedchem.1c01756. Epub 2022 Apr 25.
J Med Chem. 2022.
PMID: 35468293
Free PMC article.
Item in Clipboard
Small molecule ERK5 kinase inhibitors paradoxically activate ERK5 signalling: be careful what you wish for….
Cook SJ, Tucker JA, Lochhead PA.
Cook SJ, et al.
Biochem Soc Trans. 2020 Oct 30;48(5):1859-1875. doi: 10.1042/BST20190338.
Biochem Soc Trans. 2020.
PMID: 32915196
Free PMC article.
Review.
Item in Clipboard
Paradoxical activation of the protein kinase-transcription factor ERK5 by ERK5 kinase inhibitors.
Lochhead PA, Tucker JA, Tatum NJ, Wang J, Oxley D, Kidger AM, Johnson VP, Cassidy MA, Gray NS, Noble MEM, Cook SJ.
Lochhead PA, et al.
Nat Commun. 2020 Mar 13;11(1):1383. doi: 10.1038/s41467-020-15031-3.
Nat Commun. 2020.
PMID: 32170057
Free PMC article.
Item in Clipboard
Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4.
Myers SM, Miller DC, Molyneux L, Arasta M, Bawn RH, Blackburn TJ, Cook SJ, Edwards N, Endicott JA, Golding BT, Griffin RJ, Hammonds T, Hardcastle IR, Harnor SJ, Heptinstall AB, Lochhead PA, Martin MP, Martin NC, Newell DR, Owen PJ, Pang LC, Reuillon T, Rigoreau LJM, Thomas HD, Tucker JA, Wang LZ, Wong AC, Noble MEM, Wedge SR, Cano C.
Myers SM, et al.
Eur J Med Chem. 2019 Sep 15;178:530-543. doi: 10.1016/j.ejmech.2019.05.057. Epub 2019 May 25.
Eur J Med Chem. 2019.
PMID: 31212132
Item in Clipboard
Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation.
Lochhead PA, Clark J, Wang LZ, Gilmour L, Squires M, Gilley R, Foxton C, Newell DR, Wedge SR, Cook SJ.
Lochhead PA, et al.
Cell Cycle. 2016;15(4):506-18. doi: 10.1080/15384101.2015.1120915.
Cell Cycle. 2016.
PMID: 26959608
Free PMC article.
Item in Clipboard
Cite
Cite